Enoblituzumab, previously known as TJ-271 or MGA271, represents a novel antibody directed at CD33, the surface protein found predominantly on myeloid cells. Such molecule functions as an bispecific molecule, concurrently binding to CD33 on malignant cells and to the CD3 molecule, the component of… Read More